brand logo

Am Fam Physician. 2003;67(8):1817-1818

The debate continues over whether the degree of left ventricular outflow obstruction is an important discriminator of cardiac risk in patients with hypertrophic cardiomyopathy. Maron and colleagues conducted a prospective study of outflow obstruction in patients with hypertrophic cardiomyopathy and its association with death or heart failure.

The authors enrolled 1,101 consecutive patients diagnosed with hypertrophic cardiomyopathy at two cardiac referral centers in Italy and one in the United States. Echo-cardiographic measurement of the peak outflow gradient in the left ventricle was obtained under resting conditions, taking care to avoid any inclusion of the mitral regurgitation jet. Mean duration of follow-up was 6.3 years for risk of sudden death or progression to severe heart failure (New York Heart Association functional class III or IV).

At the time of last follow-up, 12 percent of the patient cohort had died as a result of hypertrophic cardiomyopathy, and 24 percent of the 914 surviving patients (216 patients) had progressed to severe heart failure. A peak outflow gradient of 30 mm Hg was considered the threshold at which the risk for death or heart failure progression increased, especially in patients older than 40 years (see accompanying figure). Outflow gradients higher than 30 mm Hg did not confer additional risk.

The authors concluded that echocardiographic measurement of a left ventricular outflow gradient greater than 30 mm Hg in patients with hypertrophic cardiomyopathy predicted an increased risk of death or severe heart failure, especially in patients older than 40 years.

The rightsholder did not grant rights to reproduce this item in electronic media. For the missing item, see the original print version of this publication.

Continue Reading


More in AFP

Copyright © 2003 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.